
Novocure (NVCR) Stock Forecast & Price Target
Novocure (NVCR) Analyst Ratings
Bulls say
NovoCure Ltd is positioned for accelerated revenue growth due to new study results that may allow glioblastoma patients to commence treatment 2-3 months earlier, potentially increasing revenue per patient by approximately 20-30%. The expansion of active patients in the U.S. and Germany is anticipated to contribute positively to revenue growth throughout 2026, highlighting a favorable trajectory for the company's financial performance. Additionally, incremental revenue is expected from new markets within the next 12-18 months, bolstering the existing growth drivers for the company.
Bears say
NovoCure Ltd is projected to experience a significant decline in EBITDA as revenue growth is anticipated to be gradual, resulting in a projected breakeven level by 2027. This delay in reaching profitability raises concerns regarding the company's financial viability and overall sustainability. Additionally, the reliance on revenue ramp-up from its existing product lines may pose risks to the company's growth trajectory amidst competitive pressures in the oncology market.
This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.
Novocure (NVCR) Analyst Forecast & Price Prediction
Start investing in Novocure (NVCR)
Order type
Buy in
Order amount
Est. shares
0 shares